SANTA CLARA, Calif. -- (Business Wire)
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide
access via the World Wide Web to its presentations at the RBC and
Citigroup 2013 Healthcare Conferences. The live presentations will occur
at the following dates and times:
RBC Capital Markets Healthcare Conference February 26 4:05 pm EST
Citi Global Healthcare Conference February 27 9:35 am EST
To access the live presentations via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of each of the Webcasts can be accessed for a minimum of one
month and will be available approximately 24 hours after the live
XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. Horizant®
(gabapentin enacarbil) Extended-Release Tablets is approved in the
United States for the treatment of moderate-to-severe primary restless
legs syndrome (RLS) in adults and for the management of postherpetic
neuralgia in adults. GlaxoSmithKline holds commercialization rights for Horizant
in the United States during a transition period ending on April 30,
2013, following which XenoPort will be responsible for the further
development, manufacturing and commercialization of Horizant.
Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and
is being marketed for the treatment of RLS in Japan. Astellas Pharma
Inc. holds all development and commercialization rights for Regnite
in Japan and five other Asian countries. XenoPort holds all other
world-wide rights to gabapentin enacarbil. XenoPort’s pipeline of
product candidates includes potential treatments for patients with
spasticity, Parkinson’s disease and relapsing-remitting multiple
sclerosis. To learn more about XenoPort, please visit the Website at www.XenoPort.com.
Horizant,Regnite and XENOPORT are registered trademarks
of XenoPort, Inc.
Jackie Cossmon, 408-616-7220
Source: XenoPort, Inc.
© 2017 Canjex Publishing Ltd. All rights reserved.